Highlights of weekly biotech stock moves

Basilea Pharmaceutica AG (SIX:BSLN) gained CHF1.10 to CHF36.80 last week after announcing plans to submit an MAA to EMA next half for ceftobiprole to treat severe pneumonia in the hospital setting.

BioMimetic Therapeutics Inc. (NASDAQ:BMTI) fell $0.52 (18%) to $2.39 on Wednesday after receiving a response letter from FDA for a PMA for Augment Bone Graft requesting more data. BioMimetic, which plans to submit an amendment to the PMA by mid-year, is seeking approval as an alternative to autograft in hindfoot and ankle fusion procedures (see B10)...